La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
RAPT Therapeutics Bilan de santé
Santé financière contrôle des critères 5/6
RAPT Therapeutics possède un total de capitaux propres de $109.2M et une dette totale de $0.0, ce qui porte son ratio d'endettement à 0%. Son actif total et son passif total sont $127.2M et de $18.0M.
Informations clés
0%
Ratio d'endettement
US$0
Dette
| Ratio de couverture des intérêts | n/a |
| Argent liquide | US$114.84m |
| Fonds propres | US$109.22m |
| Total du passif | US$17.96m |
| Total des actifs | US$127.18m |
Mises à jour récentes de la santé financière
Companies Like RAPT Therapeutics (NASDAQ:RAPT) Could Be Quite Risky
Jun 13
Is RAPT Therapeutics (NASDAQ:RAPT) In A Good Position To Invest In Growth?
Feb 21We Think RAPT Therapeutics (NASDAQ:RAPT) Can Afford To Drive Business Growth
Sep 12We Think RAPT Therapeutics (NASDAQ:RAPT) Can Afford To Drive Business Growth
May 10We're Hopeful That RAPT Therapeutics (NASDAQ:RAPT) Will Use Its Cash Wisely
Feb 07We're Hopeful That RAPT Therapeutics (NASDAQ:RAPT) Will Use Its Cash Wisely
Oct 12Recent updates
RAPT: CCR4 Inhibition Presses On For Now With Oncology Focus
Jul 24Companies Like RAPT Therapeutics (NASDAQ:RAPT) Could Be Quite Risky
Jun 13RAPT Therapeutics: Dip Following FDA Clinical Hold Creates Asymmetric Opportunity
May 20Is RAPT Therapeutics (NASDAQ:RAPT) In A Good Position To Invest In Growth?
Feb 21We Think RAPT Therapeutics (NASDAQ:RAPT) Can Afford To Drive Business Growth
Sep 12We Think RAPT Therapeutics (NASDAQ:RAPT) Can Afford To Drive Business Growth
May 10We're Hopeful That RAPT Therapeutics (NASDAQ:RAPT) Will Use Its Cash Wisely
Feb 07We're Hopeful That RAPT Therapeutics (NASDAQ:RAPT) Will Use Its Cash Wisely
Oct 12RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans
Jan 25RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans
Oct 15RAPT Therapeutics (RAPT) skyrockets 100% on positive RPT193 data in early-stage atopic dermatitis study
Jun 14RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans
Jun 08Should You Take Comfort From Insider Transactions At RAPT Therapeutics, Inc. (NASDAQ:RAPT)?
Mar 15We Think RAPT Therapeutics (NASDAQ:RAPT) Can Easily Afford To Drive Business Growth
Feb 15
RAPT Therapeutics' (NASDAQ:RAPT) Stock Price Has Reduced 56% In The Past Year
Jan 18RAPT Therapeutics: Interesting Asset, But Doubtful History And Bad Market Reaction
Jan 08Here's What RAPT Therapeutics, Inc.'s (NASDAQ:RAPT) Shareholder Ownership Structure Looks Like
Dec 21The Independent Chairman of the Board of RAPT Therapeutics, Inc. (NASDAQ:RAPT), William Rieflin, Just Bought 12% More Shares
Nov 23Earnings Beat: RAPT Therapeutics, Inc. (NASDAQ:RAPT) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Nov 19RAPT Therapeutics tumbles 25% despite promising FLX475 data in multiple cancers
Nov 16Analyse de la situation financière
Passif à court terme: Les actifs à court terme de RAPT ( $120.5M ) dépassent ses passifs à court terme ( $14.8M ).
Passif à long terme: Les actifs à court terme de RAPT ( $120.5M ) dépassent ses passifs à long terme ( $3.2M ).
Historique et analyse du ratio d'endettement
Niveau d'endettement: RAPT est sans dette.
Réduire la dette: RAPT n'a eu aucune dette au cours des 5 dernières années.
Bilan
Analyse des pistes de trésorerie
Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.
Piste de trésorerie stable: RAPT dispose d'une piste de trésorerie suffisante pour plus d'un an sur la base de son flux de trésorerie disponible actuel.
Prévisions de trésorerie: RAPT dispose de moins d'un an de marge de trésorerie si le flux de trésorerie disponible continue de diminuer à un taux historique de 22.6 % chaque année